MedKoo Cat#: 558597 | Name: Bornaprine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bornaprine is an anticholinergic drug used to treat Parkinson's disease due to inhibition of muscarinic or nicotinic transmission.

Chemical Structure

Bornaprine
Bornaprine
CAS#20448-86-6

Theoretical Analysis

MedKoo Cat#: 558597

Name: Bornaprine

CAS#: 20448-86-6

Chemical Formula: C21H31NO2

Exact Mass: 329.2400

Molecular Weight: 329.48

Elemental Analysis: C, 76.55; H, 9.48; N, 4.25; O, 9.71

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Bornaprine; Bornaprino; Bornaprinum;
IUPAC/Chemical Name
3-(Diethylamino)propyl 2-phenyl-2-norbornanecarboxylate
InChi Key
BDNMABJZSXTKAQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H31NO2/c1-3-22(4-2)13-8-14-24-20(23)21(18-9-6-5-7-10-18)16-17-11-12-19(21)15-17/h5-7,9-10,17,19H,3-4,8,11-16H2,1-2H3
SMILES Code
O=C(C1(C2=CC=CC=C2)CC3CCC1C3)OCCCN(CC)CC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 329.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Piccirilli M, D'Alessandro P, Testa A, Piccinin GL, Agostini L. [Bornaprine in the treatment of parkinsonian tremor]. Riv Neurol. 1985 Jan-Feb;55(1):38-45. Italian. PubMed PMID: 3895365. 2: Elmarakby SA, Clark AM, Baker JK, Hufford CD. Microbial metabolism of bornaprine, 3-(diethylamino)propyl 2-phenylbicyclo[2.2.1]heptane-2-carboxylate. J Pharm Sci. 1986 Jun;75(6):614-8. PubMed PMID: 3735109. 3: Hufford CD, Elmarakby SA, Walker LA. Anticholinergic activity of bornaprine and its metabolites in the isolated rat atrium. Pharmacology. 1991;42(1):23-7. PubMed PMID: 2057518. 4: Cantello R, Riccio A, Gilli M, Delsedime M, Scarzella L, Aguggia M, Bergamasco B. Bornaprine vs placebo in Parkinson disease: double-blind controlled cross-over trial in 30 patients. Ital J Neurol Sci. 1986 Feb;7(1):139-43. PubMed PMID: 3514543. 5: Sergi R, Massone A, Moretto S, Oggerino C, Bertolotto F, Losio L, Ottonello M. Hyperhidrosis treatment with bornaprine in the acute phase of spinal cord-injured patients. Spinal Cord. 2008 Aug;46(8):571-3. doi: 10.1038/sc.2008.12. Epub 2008 Mar 11. PubMed PMID: 18332889. 6: Hohagen F, Lis S, Riemann D, Krieger S, Meyer C, Montero RF, Grunze H, Berger M. Influence of biperiden and bornaprine on sleep in healthy subjects. Neuropsychopharmacology. 1994 Aug;11(1):29-32. PubMed PMID: 7945741. 7: Castells Rodellas A, Moragón Gordon M, Ramírez Bosca A. [Effect of bornaprine in localized hyperhidrosis]. Med Cutan Ibero Lat Am. 1987;15(4):303-5. Spanish. PubMed PMID: 3320624. 8: Bergamasco B, Cantello R, Delsedime M, Gilli M, Riccio A, Aguggia M. [Preliminary open multicenter study on the anti-tremorigenic effectiveness of bornaprine (Sormodren)]. Minerva Med. 1985 Oct 20;76(40):1877-81. Italian. PubMed PMID: 4058785. 9: Neidlein R, Pichler B, Hege G, Weymann J. [The disposition of bornaprine hydrochloride in the rat. 1. Pharmacokinetics: synthesis, plasma level and elimination]. Arzneimittelforschung. 1989 Apr;39(4):484-7. German. PubMed PMID: 2751734. 10: Mayo BC, Biggs SR, Chasseaud LF, Hawkins DR, Darragh A, O'Kelly DA. The metabolic fate of Sormodren (bornaprine hydrochloride) in animals and humans. Xenobiotica. 1980 Dec;10(12):873-88. PubMed PMID: 7210700. 11: Sancesario G, Cicardi MC, Fiermonte G, Giacomini P, Stanzione P. Effectiveness of bornaprine on parkinsonian tremor. Ital J Neurol Sci. 1984 Sep;5(3):289-93. PubMed PMID: 6500902. 12: Neidlein R, Pichler B, Hege G, Weymann J. [The disposition of bornaprine hydrochloride in the rat. 2. The metabolism of exo-epimers]. Arzneimittelforschung. 1989 May;39(5):564-9. German. PubMed PMID: 2757672. 13: Pozzoni P, Tentori F, Corti M, Pozzi C. [Rhabdomyolysis as a complication of Parkinson's disease]. G Ital Nefrol. 2002 Jan-Feb;19(1):13-7. Italian. PubMed PMID: 12165940. 14: [Managing hyperhidrosis]. MMW Fortschr Med. 2012 Jun 28;154(12):36. German. PubMed PMID: 22880296. 15: Neidlein R, Pichler B, Hege G, Weymann J. [The disposition of 2-phenyl-bicyclo[2.2.1]-heptane-2-carbonic acid (4'-diethylamino-propyl)-ester hydrochloride in the rat. 3. The metabolism of the endo-epimers of bornaprin]. Arch Pharm (Weinheim). 1988 Nov;321(11):773-80. German. PubMed PMID: 3219047. 16: Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003;(2):CD003735. Review. PubMed PMID: 12804486. 17: UMBACH W. [CLINICAL EXPERIENCES WITH DEPOT FORMS OF ANTI-PARKINSON DRUGS (AKINETON AND KR 339 KNOLL)]. Med Welt. 1963 Aug 17;33:1634-7. German. PubMed PMID: 14045620.